These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27404493)

  • 21. Genetic Variants Affecting Anti-VEGF Drug Response in Polypoidal Choroidal Vasculopathy Patients: A Systematic Review and Meta-Analysis.
    Díaz-Villamarín X; Blánquez-Martínez D; Pozo-Agundo A; Pérez-Gutiérrez AM; Muñoz-Ávila JI; Antúnez-Rodríguez A; Fernández-Gómez AE; García-Navas P; Martínez-González LJ; Dávila-Fajardo CL
    Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33198211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of CC-cytokine ligand 2 and complementary factor H Y402H polymorphisms and their interactional association with age-related macular degeneration.
    Bonyadi M; Foruzandeh Z; Mohammadian T; Fotouhi N; Soheilian M; Jabbarpoor Bonyadi MH; Javadzadeh A; Moein H; Yaseri M
    Acta Ophthalmol; 2016 Dec; 94(8):e779-e785. PubMed ID: 27316788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study.
    Lotery AJ; Gibson J; Cree AJ; Downes SM; Harding SP; Rogers CA; Reeves BC; Ennis S; Chakravarthy U;
    Ophthalmology; 2013 Dec; 120(12):2637-2643. PubMed ID: 24070809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.
    Smailhodzic D; Muether PS; Chen J; Kwestro A; Zhang AY; Omar A; Van de Ven JP; Keunen JE; Kirchhof B; Hoyng CB; Klevering BJ; Koenekoop RK; Fauser S; den Hollander AI
    Ophthalmology; 2012 Nov; 119(11):2304-11. PubMed ID: 22840423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetic influence of LOC387715/HTRA1 on the efficacy of bevacizumab treatment for age-related macular degeneration in a Korean population.
    Kang HK; Yoon MH; Lee DH; Chin HS
    Korean J Ophthalmol; 2012 Dec; 26(6):414-22. PubMed ID: 23204795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of the polymorphism Y402H in the CFH gene with response to anti-VEGF treatment in age-related macular degeneration: a systematic review and meta-analysis.
    Hong N; Shen Y; Yu CY; Wang SQ; Tong JP
    Acta Ophthalmol; 2016 Jun; 94(4):334-45. PubMed ID: 27151934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration.
    McKibbin M; Ali M; Bansal S; Baxter PD; West K; Williams G; Cassidy F; Inglehearn CF
    Br J Ophthalmol; 2012 Feb; 96(2):208-12. PubMed ID: 21558292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration.
    Lin JM; Wan L; Tsai YY; Lin HJ; Tsai Y; Lee CC; Tsai CH; Tseng SH; Tsai FJ
    Am J Ophthalmol; 2008 Jun; 145(6):1045-1051. PubMed ID: 18378209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age-related macular degeneration.
    Wegscheider BJ; Weger M; Renner W; Steinbrugger I; März W; Mossböck G; Temmel W; El-Shabrawi Y; Schmut O; Jahrbacher R; Haas A
    Ophthalmology; 2007 Apr; 114(4):738-42. PubMed ID: 17398321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).
    Hagstrom SA; Ying GS; Pauer GJ; Sturgill-Short GM; Huang J; Maguire MG; Martin DF;
    JAMA Ophthalmol; 2014 May; 132(5):521-7. PubMed ID: 24652518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The IL-8, VEGF, and CFH polymorphisms and bevacizumab in age-related macular degeneration.
    Hautamäki A; Kivioja J; Seitsonen S; Savolainen ER; Liinamaa MJ; Luoma A; Järvelä I; Immonen I
    Ophthalmology; 2014 Apr; 121(4):973-973.e1. PubMed ID: 24534755
    [No Abstract]   [Full Text] [Related]  

  • 32. VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    Krishnan R; Arora R; De Salvo G; Stinghe A; Severn PS; Pal B; Goverdhan S
    Retina; 2015 Sep; 35(9):1750-6. PubMed ID: 26237240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initial exploration of oral pazopanib in healthy participants and patients with age-related macular degeneration.
    McLaughlin MM; Paglione MG; Slakter J; Tolentino M; Ye L; Xu CF; Suttle AB; Kim RY
    JAMA Ophthalmol; 2013 Dec; 131(12):1595-601. PubMed ID: 24113783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The pharmacogenomics of CFH Y402H and wet age-related macular degeneration].
    Chen LL; Chen YY
    Zhonghua Yan Ke Za Zhi; 2017 Feb; 53(2):144-147. PubMed ID: 28260367
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Vilkeviciute A; Cebatoriene D; Kriauciuniene L; Liutkeviciene R
    Cells; 2022 Mar; 11(6):. PubMed ID: 35326447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exudative Age-Related Macular Degeneration: Association between Treatment Efficacy and Single-Nucleotide Variants in
    Vilkeviciute A; Cebatoriene D; Kriauciuniene L; Zaliuniene D; Liutkeviciene R
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 38999967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis.
    Chen G; Tzekov R; Li W; Jiang F; Mao S; Tong Y
    Sci Rep; 2015 Sep; 5():14517. PubMed ID: 26411831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The genetic variant rs4073 A→T of the Interleukin-8 promoter region is associated with the earlier onset of exudative age-related macular degeneration.
    Hautamäki A; Seitsonen S; Holopainen JM; Moilanen JA; Kivioja J; Onkamo P; Järvelä I; Immonen I
    Acta Ophthalmol; 2015 Dec; 93(8):726-33. PubMed ID: 26154559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment.
    Yamashiro K; Tomita K; Tsujikawa A; Nakata I; Akagi-Kurashige Y; Miyake M; Ooto S; Tamura H; Yoshimura N
    Am J Ophthalmol; 2012 Jul; 154(1):125-36. PubMed ID: 22465368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complement factor H Y402H polymorphism results in diminishing CD4
    Nielsen MK; Subhi Y; Falk M; Singh A; Sørensen TL; Nissen MH; Faber C
    Sci Rep; 2023 Nov; 13(1):19414. PubMed ID: 37940659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.